secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2024-07-15T23:59:59+00:00
Accession:  0001815776-24-000049
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics raises $30M from Ridgeback Capital in PIPE at $19/share
-------------------------------------------------------------------------

- PIPE financing of $30M with Ridgeback Capital at $19.00 per share; expected to close July 17, 2024.
- Proceeds to support regulatory and commercial launch activities for LNZ100, a presbyopia eye drop.
- NDA submission for LNZ100 planned mid-2024; Phase 3 CLARITY data cited as strong.
- Ridgeback Capital founder Dr. Wayne Holman expressed support; shares unregistered with resale registration to be filed.
- Existing cash plus PIPE proceeds to fund pre-commercial and potential launch activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000049/0001815776-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000049/lenz-20240714.htm
  HTML page:      https://secwatch.observer/filing/0001815776-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer